Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Trial Profile

Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Ozanezumab (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 02 Dec 2014 Planned End Date changed from 1 May 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 02 Dec 2014 Planned primary completion date changed from 1 May 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top